Combined analysis of DNA ploidy index and N-myc genomic content in neuroblastoma.
The aim of the study was to assess, in a group of nonselected patients with neuroblastoma, the prognostic value of both N-myc gene amplification and DNA ploidy index, taking into account potential confounding factors such as age and stage. Of 59 patients studied, 23 were younger than 1 year at diagnosis, 31 presented with stage IV, 10 with stage III, 5 with stage II, 8 with stage I, and 4 with stage IV-S. N-myc genomic content was analyzed by Southern blot hybridization technique and N-myc amplification (greater than or equal to 3 copies/haploid genome) was present in 6 stage IV, 2 stage III, and 1 stage IV-S. The DNA ploidy index was analyzed by flow cytometry. Of the 59 neuroblastomas, 26 were diploid (DNA index, 1) and 33 were aneuploid (DNA index, greater than 1). The majority of the aneuploid tumors (28 of 33) were near-triploid with DNA indexes between 1.25 and 1.68, 4 were near-diploid (DNA index up to 1.18), and 1 was hypotetraploid (DNA index, 1.85). The proportion of near-triploid tumors was significantly greater among patients under 1 year of age and among patients presenting with stages I, II, and IV-S. Interestingly, 0 of 28 near-triploid neuroblastomas exhibited N-myc gene amplification, compared to 9 of 31 in the group of diploid, near-diploid, and hypotetraploid tumors (Fisher's exact test, P less than 0.001). Four factors were significantly related to a high risk of relapse in univariate analysis, i.e., age, stage, DNA index, and N-myc amplification. In multivariate analysis, only N-myc amplification and the DNA index remained significantly associated with a high risk of relapse. The 2-year disease-free survival rate was 94% (95% confidence interval, 77-98%) for patients with near-triploid neuroblastoma, compared to 45 and 11% (95% confidence interval, 32-70 and 4-23%) for patients with diploid or near-diploid tumors, without and with N-myc amplification, respectively. We concluded that the combination of N-myc and DNA index should be included in routine management of neuroblastoma.
Bourhis
J
J
Laboratory of Molecular and Clinical Pharmacology, Institut Gustave Roussy, Villejuif, France.
De Vathaire
F
F
Wilson
G D
GD
Hartmann
O
O
Terrier-Lacombe
M J
MJ
Boccon-Gibod
L
L
McNally
N J
NJ
Lemerle
J
J
Riou
G
G
Bénard
J
J
D000367:Age Factors; D015139:Blotting, Southern; D004273:DNA, Neoplasm / Q000235:genetics*; D005784:Gene Amplification; D006801:Humans; D009447:Neuroblastoma / Q000235:genetics*; D011003:Ploidies; D011379:Prognosis; D016271:Proto-Oncogene Proteins c-myc / Q000235:genetics*; D011519:Proto-Oncogenes; D012307:Risk Factors; D016019:Survival Analysis
D004273:DNA, Neoplasm; D016271:Proto-Oncogene Proteins c-myc